Uğur, F.Gülcü, NebahatBoyacı, A.2021-06-232021-06-2320070001-5172https://doi.org/10.1111/j.1399-6576.2006.01202.xhttps://hdl.handle.net/20.500.12491/6101Sir, Pain is one of the most important symptoms of end-stage cancer that needs to be controlled. Dexmedetomidine is an alpha2 agonist with sedative and analgesic properties (1). Intrathecal dexmedetomidine for the relief of cancer pain has not been reported in the literature previously. In this communication, the use of intrathecal dexmedetomidine-supplemented morphine is reported in a patient with cancer.eninfo:eu-repo/semantics/openAccessCancer PainLetter10.1111/j.1399-6576.2006.01202.x513388388171559392-s2.0-33847069614Q1WOS:000244225800026Q2